Scleroderma Research | https://external.fcrk1-3.fna.fbcdn.net/emg1/v/t13/8700233622198339838?url=https%3A%2F%2Frfums-bigtree.s3.amazonaws.com%2Ffiles%2Fcallouts%2Fxt3x0832.jpg
Scleroderma Research | https://external.fcrk1-3.fna.fbcdn.net/emg1/v/t13/8700233622198339838?url=https%3A%2F%2Frfums-bigtree.s3.amazonaws.com%2Ffiles%2Fcallouts%2Fxt3x0832.jpg
Thanks to a five-year, $780,000 grant awarded by Canadian Institutes of Health Research, our biotech spinout BLR Bio’s research collaboration with research partner Dr. Andy Leask from the University of Saskatchewan is another step closer to finding a new therapy for people with debilitating scleroderma.
BLR Bio Founder and CEO Bruce Riser, PhD, continues to maximize the development process by prioritizing and expanding this long-term collaboration.
“International collaborative research is key to the discovery of new treatments for debilitating diseases like scleroderma,” said Dr. Ronald Kaplan, RFU executive vice president for research.
Original source can be found here.
Alerts Sign-up